Dr. Gasparetto on Next Steps With Selinexor and Daratumumab in Multiple Myeloma

Cristina Gasparetto, MD, assistant professor of medicine, member of the Duke Cancer Institute, discusses the next steps with selinexor and daratumumab (Darzalex) in multiple myeloma.

In a phase lb study, the combination of selinexor and daratumumab was evaluated in patients with relapsed/refractory multiple myeloma who were previously exposed to proteasome inhibitors and immunomodulatory drugs.

This combination will move onto a phase II study with more patients, says Gasparetto, in order to effectively evaluate response, side effects, and efficacy.